drugset / Trial / NCT06917508

A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants

NCT06917508

Phase 1 Completed 24 enrolled Enanta Pharmaceuticals, Inc
NaSingle-groupOpen-labelBasic science

Summary

The primary aim of this study is to assess the effect of EDP-323 on the pharmacokinetics and safety of midazolam, caffeine, and rosuvastatin in healthy adult participants.

Timeline

Start
2025-03-13
Primary completion
2025-06-06
Completion
2025-06-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Caffeine Small molecule
Subject EDP-323 Unknown
Subject Midazolam Small molecule
Subject Rosuvastatin Small molecule